NO930201L - Substituerte bicykliske bis-arylforbindelser med selektivleukotrien-b4-antagonistaktivitet, deres fremstilling og bruk - Google Patents

Substituerte bicykliske bis-arylforbindelser med selektivleukotrien-b4-antagonistaktivitet, deres fremstilling og bruk

Info

Publication number
NO930201L
NO930201L NO93930201A NO930201A NO930201L NO 930201 L NO930201 L NO 930201L NO 93930201 A NO93930201 A NO 93930201A NO 930201 A NO930201 A NO 930201A NO 930201 L NO930201 L NO 930201L
Authority
NO
Norway
Prior art keywords
selective
preparation
leukotrien
antagonist activity
substituted bicyclic
Prior art date
Application number
NO93930201A
Other languages
English (en)
Norwegian (no)
Other versions
NO930201D0 (no
Inventor
Norbert Dereu
Wolfram Hendel
Richard Labaudiniere
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO930201D0 publication Critical patent/NO930201D0/no
Publication of NO930201L publication Critical patent/NO930201L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/205—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
NO93930201A 1990-07-24 1993-01-21 Substituerte bicykliske bis-arylforbindelser med selektivleukotrien-b4-antagonistaktivitet, deres fremstilling og bruk NO930201L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9009453A FR2665159B1 (fr) 1990-07-24 1990-07-24 Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
PCT/EP1991/001341 WO1992001675A2 (fr) 1990-07-24 1991-07-18 Composes bis-aryle bicycliques substitues ayant une activite antagoniste selective sur le leukotriene b4, leur preparation et utilisation dans des compositions pharmaceutiques

Publications (2)

Publication Number Publication Date
NO930201D0 NO930201D0 (no) 1993-01-21
NO930201L true NO930201L (no) 1993-01-21

Family

ID=9399053

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930201A NO930201L (no) 1990-07-24 1993-01-21 Substituerte bicykliske bis-arylforbindelser med selektivleukotrien-b4-antagonistaktivitet, deres fremstilling og bruk

Country Status (15)

Country Link
US (2) US5366982A (fr)
EP (1) EP0540604A1 (fr)
JP (1) JPH05508845A (fr)
AU (1) AU8194891A (fr)
CA (1) CA2087848A1 (fr)
CZ (1) CZ403192A3 (fr)
FI (1) FI930256A (fr)
FR (1) FR2665159B1 (fr)
HU (1) HUT68663A (fr)
IE (1) IE912589A1 (fr)
IL (1) IL98921A0 (fr)
NO (1) NO930201L (fr)
PT (1) PT98438A (fr)
WO (1) WO1992001675A2 (fr)
ZA (1) ZA915759B (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
FR2705959B1 (fr) * 1993-06-01 1995-08-11 Oreal Procédé de synthèse stéréospécifique de leucotriène B4 sous sa configuration 6Z, 8E, 10E et produits intermédiaires.
TW416948B (en) * 1993-12-28 2001-01-01 Merck & Co Inc Process for the preparation of leukotriene antagonists
JP2866202B2 (ja) * 1994-04-13 1999-03-08 エフ・ホフマン−ラ ロシュ アーゲー 置換ピリジンロイコトリエンｂ▲下４▼拮抗物質
US5461049A (en) * 1994-05-27 1995-10-24 Warner-Lambert Company Amide tetrazole ACAT inhibitors
US5556990A (en) * 1994-12-16 1996-09-17 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polyarylcarbamoylaza- and -carbamoylalkanedioic acids
US6103465A (en) * 1995-02-14 2000-08-15 The Perkin-Elmer Corporation Methods and reagents for typing HLA class I genes
US5571825A (en) * 1995-03-31 1996-11-05 Warner-Lambert Company Method of selectively inhibiting prostaglandin G/H synthase-2
CA2224563A1 (fr) 1995-06-12 1996-12-27 G.D. Searle & Co. Traitement d'inflammations par une combinaison d'un inhibiteur de la cyclooxygenase-2 et d'un antagoniste du recepteur de leukotriene b4
DE69733338T2 (de) * 1996-02-13 2006-03-16 G.D. Searle & Co., Chicago Zubereitungen, enthaltend einen cyclooxygenase-2-inhibitor und einen leukotrien-b4-rezeptor-antagonisten
US6416733B1 (en) 1996-10-07 2002-07-09 Bristol-Myers Squibb Pharma Company Radiopharmaceuticals for imaging infection and inflammation
AU736481C (en) * 1996-10-07 2002-06-06 Du Pont Pharmaceuticals Company Radiopharmaceuticals for imaging infection and inflammation
US20030124053A1 (en) * 1996-10-07 2003-07-03 Barrett John Andrew Radiopharmaceuticals for imaging infection and inflammation
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
AU6572298A (en) * 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating ischemia reperfusion injury
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
CA2360740A1 (fr) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
BR0014254A (pt) * 1999-09-08 2002-08-27 Sloan Kettering Inst Cancer Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6812237B2 (en) 2000-05-15 2004-11-02 Novartis Ag N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
US20020198207A1 (en) * 2000-05-18 2002-12-26 Kath John Charles Novel Hexanoic acid derivatives
US6696466B1 (en) * 2000-09-07 2004-02-24 Leslie Joe Dunaway Methods of treating select neuronal inflammatory disorders using hydroxyalkylquinolines
KR100883184B1 (ko) 2000-12-11 2009-02-12 암젠 인코포레이션 Ｃｘｃｒ3 길항제
WO2002076438A2 (fr) * 2001-03-23 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Ligands flt-1 et utilisations de ceux-ci
TWI316055B (fr) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
MY133579A (en) 2001-07-13 2007-11-30 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
EP1474425B9 (fr) * 2002-01-07 2008-07-02 Eisai Co., Ltd. Deazapurines et leurs utilisations
CA2475879A1 (fr) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis de quinazolinones
US6921752B2 (en) * 2002-03-26 2005-07-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of LTB4 antagonists in veterinary medicine
US7271266B2 (en) 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
WO2003097053A1 (fr) * 2002-05-09 2003-11-27 Cytokinetics, Inc. Composes, compositions et procedes
JP2006508030A (ja) * 2002-05-09 2006-03-09 サイトキネティクス・インコーポレーテッド ピリミジノン化合物、組成物および方法
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003236527A1 (en) * 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004009036A2 (fr) * 2002-07-23 2004-01-29 Cytokinetics, Inc. Composes, compositions et procedes
AU2003262747A1 (en) * 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
EP1546115A4 (fr) * 2002-09-27 2010-08-04 Merck Sharp & Dohme Pyrimidines substituees
EP1558083A4 (fr) * 2002-09-30 2008-04-16 Cytokinetics Inc Composes, compositions, et procedes
MXPA05006425A (es) 2002-12-16 2005-08-19 Astrazeneka Uk Ltd Procedimiento para la preparacion de compuestos de pirimidina.
JP2006523693A (ja) * 2003-04-01 2006-10-19 メモリアル スローン−ケタリング キャンサー センター ヒドロキサム酸化合物およびその使用方法
MXPA05011103A (es) 2003-04-16 2005-12-12 Hoffmann La Roche Compuestos de quinazolina.
US20040254178A1 (en) * 2003-04-16 2004-12-16 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1660094A4 (fr) 2003-08-26 2009-09-16 Univ Colorado Inhibiteurs de l'activite de la protease serine et leurs utilisations dans des methodes et preparations de traitement d'infections bacteriennes
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
JP2007510652A (ja) * 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッド ピリミジン−４−オン化合物、組成物、および方法
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
EP1692112A4 (fr) * 2003-12-08 2008-09-24 Cytokinetics Inc Composes, compositions, et methodes associees
WO2005097137A2 (fr) * 2004-03-31 2005-10-20 The Scripps Research Institute Inhibiteurs de proteines kinases ameliores a base de quinazoline
RU2006144121A (ru) * 2004-05-14 2008-06-20 Айрм Ллк (Us) Соединения и композиции в качестве модуляторов ppar рецепторов, активируемых пролифератором пероксисом
US7541472B2 (en) * 2004-05-24 2009-06-02 Cropsolution, Inc. 3-Aryl-3-hydroxy-2-methylenepropionic acid esters as fungicides
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
DE102005044156A1 (de) * 2005-09-15 2007-03-29 Riemser Arzneimittel Ag Substituierte Acetophenonderivate
RS54522B1 (en) * 2005-12-22 2016-06-30 Newron Pharmaceuticals S.P.A. 2-Phenylethylamino Derivatives as Modulators of Calcium and (or Sodium) Channels
DE102006021872B4 (de) * 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2662852A1 (fr) * 2006-09-07 2008-03-13 Allergan, Inc. Composes heteroaromatiques presentant une activite biologique agoniste et/ou antagoniste sur le recepteur sphingosine-1-phosphate (s1p)
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
CA2680122A1 (fr) 2007-03-05 2008-09-18 Kyowa Hakko Kirin Co., Ltd. Composition pharmaceutique
US8093253B2 (en) 2008-03-06 2012-01-10 Hoffmann-La Roche Inc. Leukotriene B4 inhibitors
WO2010006939A1 (fr) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Acides aminotétrahydroindazoloacétiques
ES2386948T3 (es) 2008-07-15 2012-09-07 F. Hoffmann-La Roche Ag Ácidos aminotetrahidroindazoloacéticos
WO2010018109A2 (fr) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Aminotétralines substituées
EP2321268A2 (fr) 2008-08-15 2011-05-18 F. Hoffmann-La Roche AG Bi-aryle aminotétralines
US8124629B2 (en) 2008-11-17 2012-02-28 Hoffmann-La Roche Inc. Naphthylacetic acids
NZ591914A (en) 2008-11-17 2013-04-26 Hoffmann La Roche Naphthylacetic acids
US8188090B2 (en) 2008-11-17 2012-05-29 Hoffman-La Roche Inc. Naphthylacetic acids
EP2379076B1 (fr) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Inhibiteurs de la phosphodiestérase et utilisations de ces derniers
US8586751B2 (en) 2009-06-12 2013-11-19 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
CN106035343B (zh) 2010-07-20 2019-07-02 韦斯塔隆公司 三嗪类和嘧啶类杀虫剂
CA2816957A1 (fr) 2010-11-07 2012-05-10 Targegen, Inc. Compositions et procedes de traitement de la myelofibrose
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
CA2848631C (fr) 2011-09-16 2019-10-01 Hetero Research Foundation Chlorhydrate de rilpivirine
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
JP6322704B2 (ja) 2013-06-27 2018-05-09 エルジー・ケム・リミテッド Ｇｐｒ１２０アゴニストとしてのビアリール誘導体
MX2017002610A (es) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
DK3239143T3 (da) * 2014-12-24 2023-04-11 Lg Chemical Ltd Biarylderivat som gpr120-agonist
WO2017007755A1 (fr) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. N-aminophényl-amides hétérocycliques en tant qu'inhibiteurs de l'histone désacétylase
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
WO2017048864A1 (fr) * 2015-09-14 2017-03-23 The Regents Of The University Of California Préparation d'acides gras de furane à partir de 5-(chlorométhyl)furfural
JP6756925B2 (ja) 2017-01-11 2020-09-16 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼの二環式阻害剤
DK3664802T3 (en) 2017-08-07 2022-05-30 Alkermes Inc Bicyclic inhibitors of histone deacetylase
WO2019079759A1 (fr) * 2017-10-19 2019-04-25 Laurence Rahme Composés anti-persistance et anti-virulence à large spectre

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5035M (fr) * 1964-07-28 1967-05-02
JPS5758666A (en) * 1980-09-24 1982-04-08 Otsuka Pharmaceut Co Ltd Alkanoic acid derivative
DE3211395A1 (de) * 1982-03-27 1983-09-29 Hoechst Ag, 6230 Frankfurt Pyridon-2-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
FR2582514B1 (fr) * 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
WO1987005510A1 (fr) * 1986-03-13 1987-09-24 Rorer International (Overseas) Inc. Tetrazoles de thioether ou d'ether de quinolinyle utilises comme agents pour le traitement de troubles d'hypersensibilite
CA1315279C (fr) * 1987-01-12 1993-03-30 Nancy Grace Bollinger Agents antiinflammatoires
CA1320490C (fr) * 1987-01-12 1993-07-20 Darrel M. Gapinski Agents antiinflammatoires
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
US5004743A (en) * 1987-11-25 1991-04-02 Merck Frosst Canada, Inc. Pyridyl styrene dialkanoic acids as anti-leukotriene agents
WO1989011279A1 (fr) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Compose heteropolycyclique non fusionne ayant une interaction avec des acides nucleiques
DE4445996C2 (de) * 1994-12-22 2002-10-24 Bosch Gmbh Robert Verfahren zur Auslösung von Rückhaltemitteln

Also Published As

Publication number Publication date
WO1992001675A3 (fr) 1992-08-06
EP0540604A1 (fr) 1993-05-12
US5492915A (en) 1996-02-20
JPH05508845A (ja) 1993-12-09
CZ403192A3 (en) 1993-09-15
FI930256A0 (fi) 1993-01-22
IL98921A0 (en) 1992-07-15
NO930201D0 (no) 1993-01-21
HU9300190D0 (en) 1993-04-28
PT98438A (pt) 1992-05-29
FR2665159B1 (fr) 1992-11-13
ZA915759B (en) 1992-05-27
FI930256A (fi) 1993-01-22
HUT68663A (en) 1995-07-28
US5366982A (en) 1994-11-22
CA2087848A1 (fr) 1992-01-25
IE912589A1 (en) 1992-01-29
FR2665159A1 (fr) 1992-01-31
AU8194891A (en) 1992-02-18
WO1992001675A2 (fr) 1992-02-06

Similar Documents

Publication Publication Date Title
NO930201L (no) Substituerte bicykliske bis-arylforbindelser med selektivleukotrien-b4-antagonistaktivitet, deres fremstilling og bruk
EA200601235A1 (ru) Производные тиазола
ES2044836T3 (es) Derivado de la piperidina, su utilizacion y compuesto farmaceutico que lo contiene.
NO900306L (no) Fremgangsmaate for fremstilling av nye pyrazolopyridin-forbindelser.
ATE44528T1 (de) Arzneimittel mit antipsychotischer wirkung.
EP1069111A4 (fr) Derives d'indole exer ant une activite antivirale
NO874454D0 (no) Nye derivater av benzimidazoler med anti-ulcusaktivitet og fremgangsmaate for deres fremstilling.
ATE910T1 (de) Derivate des 3.5-dihydroxypentansaeureesters mit antihyperlipaemischer aktivitaet, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
DK506587D0 (da) Imidderivater
CA2114727A1 (fr) Derives quinoline utilises comme immunostimulants
DE3665711D1 (de) Novel guanidinomethylbenzoic acid derivatives
MX9300222A (es) Nuevos derivados de arilcicloalquilo, su preparacion y su utilizacion.
LU83820A1 (fr) Derives de la 2-oxoazetidine,leur preparation et leur utilisation
IE43715L (en) Rodenticidal diphenylamines
ATE39357T1 (de) Derivate von griseolicsaeure und ihre verwendung.
DE3782347D1 (de) Hetaryl-oxy-beta-carbolinderivate, ihre herstellung und verwendung als arzneimittel.
MY101142A (en) 1, 4-dihydropyridine derivative, process for production thereof, and pharmaceutical use thereof.
IE40052B1 (en) Indole derivatives
GB1531963A (en) Pyrido(1,2alpha)pyrimidine derivatives
GB1158868A (en) Novel 2,4-Disubstituted 7- and 8-Chloroquinolines, the preparation thereof and Compositions containing the same
ATE50248T1 (de) Ein imidazolidintrion-derivat oder ein seiner pharmazeutisch akzeptierbaren salze enthaltende pharmazeutische zusammenstellung.
EA199900528A1 (ru) Новые производные эритромицина, способ их получения и применения в качетве медикаментов
GB1498535A (en) Heterocyclic compounds
GB1425706A (en) Piperidine derivatives
YU239790A (sh) Sredstva za zatiranje škodljivcev